https://trigemxbio.com/kallyope-announces-positive-results-from-phase-2b-study-of-elismetrep-for-the-acute-treatment-of-migraine/ 2026-09-28T15:52:24+00:00 https://trigemxbio.com/kallyope-to-present-phase-2b-study-results-for-elismetrep-for-the-acute-treatment-of-migraine-at-the-2026-american-academy-of-neurology-annual-meeting/ 2026-09-28T15:53:02+00:00 https://trigemxbio.com/kallyopes-phase-2b-study-of-elismetrep-a-novel-approach-for-treating-migraine-presented-at-the-american-academy-of-neurology-annual-meeting/ 2026-09-28T15:53:36+00:00 https://trigemxbio.com/kallyope-presents-new-data-on-novel-trpm8-channel-blocker-elismetrep-for-the-acute-treatment-for-migraine-at-the-american-headache-society-68th-annual-scientific-meeting/ 2026-09-28T15:54:11+00:00 https://trigemxbio.com/trigemx-bio-announces-94m-financing-and-initiation-of-phase-3-trials-for-elismetrep-a-potential-first-in-class-treatment-for-migraine/ 2026-10-01T13:00:39+00:00